MarketPulse
M

$MESO

5 articles found
4 positive
0 negative
1 neutral
BenzingaBenzinga··Equity-Insider.Com

Biotech Breakthrough: Avaí Bio Moves Anti-Aging Protein Therapy Into Production

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.
MESOMNKDLGVNAVAILCTXregenerative medicinecell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.
MESORyoncil®cellular medicines
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Taps Regeneron Veteran as Clinical Chief to Expand Cell Therapy Pipeline

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.
MESOclinical developmentRyoncil®
BenzingaBenzinga··Prnewswire

Cell Therapies Graduate to Mass Production as Market Eyes $8.2B Prize

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.
MESOFATEFBLGLGVNbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval